Literature DB >> 20139751

The evolution of protease mutation 76V is associated with protease mutation 46I and gag mutation 431V.

Elena Knops1, Ina Kemper, Eugen Schülter, Herbert Pfister, Rolf Kaiser, Jens Verheyen.   

Abstract

Recently, first-line lopinavir failure was observed due to protease mutation 76V. In the present study, we found 76V associated with protease mutation 46I and gag cleavage-site mutation 431V. Longitudinal analysis of patients failing protease inhibitor therapies demonstrated that 76V strictly occurs either together with 46I and/or 431V or in HIV isolates already harbouring one of both mutations. Therefore, all three mutations seem to cooperate in terms of protease inhibitor resistance.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 20139751     DOI: 10.1097/QAD.0b013e328336784d

Source DB:  PubMed          Journal:  AIDS        ISSN: 0269-9370            Impact factor:   4.177


  6 in total

1.  Mutational patterns in the frameshift-regulating site of HIV-1 selected by protease inhibitors.

Authors:  Elena Knops; Léa Brakier-Gingras; Eugen Schülter; Herbert Pfister; Rolf Kaiser; Jens Verheyen
Journal:  Med Microbiol Immunol       Date:  2011-12-27       Impact factor: 3.402

2.  Prevalence, mutation patterns, and effects on protease inhibitor susceptibility of the L76V mutation in HIV-1 protease.

Authors:  Thomas P Young; Neil T Parkin; Eric Stawiski; Tami Pilot-Matias; Roger Trinh; Dale J Kempf; Michael Norton
Journal:  Antimicrob Agents Chemother       Date:  2010-08-30       Impact factor: 5.191

3.  Polymorphism in Gag gene cleavage sites of HIV-1 non-B subtype and virological outcome of a first-line lopinavir/ritonavir single drug regimen.

Authors:  Jade Ghosn; Constance Delaugerre; Philippe Flandre; Julie Galimand; Isabelle Cohen-Codar; François Raffi; Jean-François Delfraissy; Christine Rouzioux; Marie-Laure Chaix
Journal:  PLoS One       Date:  2011-09-20       Impact factor: 3.240

4.  HIV-1 Gag C-terminal amino acid substitutions emerging under selective pressure of protease inhibitors in patient populations infected with different HIV-1 subtypes.

Authors:  Guangdi Li; Jens Verheyen; Kristof Theys; Supinya Piampongsant; Kristel Van Laethem; Anne-Mieke Vandamme
Journal:  Retrovirology       Date:  2014-09-25       Impact factor: 4.602

5.  Comparing mutational pathways to lopinavir resistance in HIV-1 subtypes B versus C.

Authors:  Susana Posada-Céspedes; Gert Van Zyl; Hesam Montazeri; Jack Kuipers; Soo-Yon Rhee; Roger Kouyos; Huldrych F Günthard; Niko Beerenwinkel
Journal:  PLoS Comput Biol       Date:  2021-09-07       Impact factor: 4.475

Review 6.  Human Immunodeficiency Virus Gag and protease: partners in resistance.

Authors:  Axel Fun; Annemarie M J Wensing; Jens Verheyen; Monique Nijhuis
Journal:  Retrovirology       Date:  2012-08-06       Impact factor: 4.602

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.